(Integral Molecular) Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4 million by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome. With this Phase 2 SBIR grant, Integral Molecular builds on its successful Phase 1 SBIR program isolating antibodies with high specificity and high affinity for CB1.

Original source: https://www.eurekalert.org/pub_releases/2019-03/im-imm031119.php